Credo Capital Management’s Salix Pharmaceuticals SLXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2013
Q4
$444K Sell
4,938
-9,113
-65% -$727K 1.91% 4
2013
Q3
$940K Sell
14,051
-24,818
-64% -$1.71M 1.62% 27
2013
Q2
$2.57M Buy
+38,869
New +$2.22M 1.98% 14

Other funds holding SLXP

Credo Capital Management's SLXP Position: Q4 2013 in Review

Credo Capital Management reduced its Salix Pharmaceuticals (SLXP) stake by 65% in Q4 2013, selling an estimated $727K and leaving 4,938 shares worth $444K. The position accounts for 1.91% of the portfolio, ranked #4.

Credo Capital Management first reported a position in SLXP in Q2 2013 and has held it in 3 quarters since. The position peaked at $2.57M in Q2 2013. 245 funds tracked by Wall St. Rank hold SLXP as of Q4 2013.

  • Credo Capital Management held 4,938 shares of Salix Pharmaceuticals worth $444K as of Q4 2013.
  • Credo Capital Management sold 9,113 Salix Pharmaceuticals shares in Q4 2013, an estimated $727K.
  • Salix Pharmaceuticals made up 1.91% of Credo Capital Management's portfolio in Q4 2013, its #4 holding.
  • Credo Capital Management first reported a position in Salix Pharmaceuticals in Q2 2013 and has held it in 3 quarters since.
  • Credo Capital Management's Salix Pharmaceuticals position peaked at $2.57M in Q2 2013.
  • 245 funds tracked by Wall St. Rank held Salix Pharmaceuticals as of Q4 2013.

Based on Credo Capital Management's 13F filing for Q4 2013, filed 24 Jan 2014.